For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
21
views
90
references
 Top references
cited by
5
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      648
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Progress and challenges in the vaccine-based treatment of head and neck cancers

      review-article
      Author(s): 1 ,
      Publication date (Electronic):
      Journal: Journal of Experimental & Clinical Cancer Research : CR
      Publisher: BioMed Central

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Head and neck (HN) cancer represents one of the most challenging diseases because the mortality remains high despite advances in early diagnosis and treatment. Although vaccine-based approaches for the treatment of advanced squamous cell carcinoma of the head and neck have achieved limited clinical success, advances in cancer immunology provide a strong foundation and powerful new tools to guide current attempts to develop effective cancer vaccines. This article reviews what has to be rather what has been done in the field for the development of future vaccines in HN tumours.

          Related collections

          Most cited references90

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer immunotherapy: moving beyond current vaccines.

          Steven Rosenberg, James Yang, Nicholas Restifo (2004)
          Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
          Article 0 comments Cited 597 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reporting results of cancer treatment.

            A Miller, B Hoogstraten, M. Staquet … (1981)
            On the initiative of the World Health Organization, two meetings on the Standardization of Reporting Results of Cancer Treatment have been held with representatives and members of several organizations. Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease-free interval, and reporting results of therapy. These recommendations, already endorsed by a number of organizations, are proposed for international acceptance and use to make it possible for investigators to compare validly their results with those of others.
            Article 0 comments Cited 502 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Enhancement of antitumor immunity by CTLA-4 blockade.

              D Leach, M. Krummel, J Allison (1996)
              One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
              Article 0 comments Cited 407 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): J Exp Clin Cancer Res
                Title: Journal of Experimental & Clinical Cancer Research : CR
                Publisher: BioMed Central
                ISSN (Print): 0392-9078
                ISSN (Electronic): 1756-9966
                Publication date Collection: 2009
                Publication date (Electronic): 27 May 2009
                Volume: 28
                Issue: 1
                Page: 69
                Affiliations
                [1 ]Laboratory of Virology – Regina Elena Cancer Institute – Via Messi d'Oro 156-00158 Rome, Italy
                Article
                Publisher ID: 1756-9966-28-69
                DOI: 10.1186/1756-9966-28-69
                PMC ID: 2695420
                PubMed ID: 19473517
                SO-VID: 8ba5f897-d100-4427-bfff-ed3b886bf678
                Copyright © Copyright © 2009 Venuti; licensee BioMed Central Ltd.
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : 25 March 2009
                Date accepted : 27 May 2009
                Categories
                Subject: Review

                ScienceOpen disciplines: Oncology & Radiotherapy
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy

                Comments

                Comment on this article

                scite_

                Similar content648

                See all similar

                Cited by5

                See all cited by

                Most referenced authors2,231

                See all reference authors